Category: Uncategorized

GILEAD’S $1.88 BILLION BET ON VIR: THE NEXT SOLID TUMOR BREAKTHROUGH MAY DEPEND ON CONTROLLING T-CELL ACTIVATION, NOT JUST TARGETING CANCER

15/10/2026 Published by HealthBiz

Key Development Gilead Sciences has entered a collaboration with Vir Biotechnology worth up to approximately US$1.88 billion to develop three... Read more

Tags: #Global Trends

SANOFI ESCAPES EU ANTITRUST FINE: WHY VACCINE COMPETITION IS BECOMING A BATTLE OVER SCIENTIFIC CREDIBILITY, NOT JUST MARKET SHARE

15/10/2026 Published by HealthBiz

Key Development Sanofi has avoided a potentially substantial EU antitrust fine after the European Commission accepted legally binding commitments addressing... Read more

Category: Uncategorized

Tags: #Global Trends

LONG CHAU BRINGS DOCTORS INTO PHARMACIES: VIETNAM’S PHARMACY MARKET IS MOVING FROM MEDICINE RETAIL TOWARD CONTINUOUS HEALTHCARE

14/10/2026 Published by HealthBiz

Key Development FPT Long Chau has formed a strategic partnership with the Vietnam Young Physicians Association, supported by 16 multinational... Read more

Category: Uncategorized

Tags: #Vietnam

NUTIFOOD’S HOSPITAL PARTNERSHIP: VIETNAM’S HERBAL INGREDIENTS COULD BECOME A SCIENCE-DRIVEN NUTRITION INDUSTRY

14/10/2026 Published by HealthBiz

Key Development Nutifood has partnered with Ho Chi Minh City Traditional Medicine Hospital to develop nutrition products using Vietnamese medicinal... Read more

Category: Uncategorized

Tags: #Vietnam

J&J’S ICOTYDE SURPASSES 20,000 PATIENT STARTS: THE BIGGER OPPORTUNITY IS EXPANDING THE PSORIASIS MARKET, NOT JUST WINNING SHARE FROM BIOLOGICS

14/10/2026 Published by HealthBiz

Key Development Johnson & Johnson's oral IL-23 receptor inhibitor Icotyde (icotrokinra) has surpassed 20,000 patient starts through nearly 9,000 prescribers... Read more

Category: Uncategorized

Tags: #Global Trends

LONZA’S HIGH-30S MARGIN AMBITION: WHY THE NEXT CDMO COMPETITIVE ADVANTAGE IS CAPITAL PRODUCTIVITY, NOT JUST MANUFACTURING SCALE

14/10/2026 Published by HealthBiz

Key Development Lonza has upgraded its medium-term financial ambitions, targeting 10–13% average organic sales growth at constant exchange rates and... Read more

Category: Uncategorized

Tags: #Global Trends

ZEALAND PHARMA’S $1.2 BILLION AI OBESITY BET: THE NEXT COMPETITIVE ADVANTAGE MAY BE ENGINEERING BETTER BIOLOGY, NOT JUST BETTER GLP-1 DRUGS

14/10/2026 Published by HealthBiz

Key Development Zealand Pharma has entered a collaboration with Generate Biomedicines worth up to nearly US$1.2 billion in milestone payments,... Read more

Category: Uncategorized

Tags: #Global Trends

VIETNAM’S VND 170 BILLION HOSPITAL PROBLEM: THE REAL COST IS NOT IDLE EQUIPMENT, BUT FAILED CAPITAL PRODUCTIVITY

14/10/2026 Published by HealthBiz

Key Development A nearly VND 170 billion hospital investment in Hue has exposed a fundamental weakness in healthcare infrastructure development:... Read more

Category: Uncategorized

Tags: #Vietnam